Many studies have suggested that it acts directly by liver kinase B1 (LKB1)-dependent and 5′ adenosine monophosphate (AMP)-activated protein kinase (AMPK)-dependent suppression of the mammalian target of rapamycin (mTOR) pathway which inhibits protein formation and hence tumor cell multiplication and indirectly by decreasing insulin-mediated tumor growth and through its anti-inflammatory action [10-12]. Here, STK11 is linked to neoplasm.